Sandbox Reserved 895: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Ivan E. Wang (talk | contribs) No edit summary |
Ivan E. Wang (talk | contribs) No edit summary |
||
| Line 33: | Line 33: | ||
Historically (''R'')-Emixustat was tested as a possible treatment for dry (atrophic) age-related macular degeneration in Phase IIb/III clinical trials but failed to show clinical outcomes due to significant pharmacokinetic and pharmacodynamic short falls. | Historically (''R'')-Emixustat was tested as a possible treatment for dry (atrophic) age-related macular degeneration in Phase IIb/III clinical trials but failed to show clinical outcomes due to significant pharmacokinetic and pharmacodynamic short falls. | ||
[[Media:RPE65 with Emixustat Spin]] | [[Media:RPE65 with Emixustat Spin|thumb|right|512 px|alt=Figure 3.5: RPE65 and Emixustat| Figure 3: RPE65 with Emixustat]] | ||
</StructureSection> | </StructureSection> | ||
